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bladder base and urethral radiation injuries. Our ability to 
predict these injuries prior to radiotherapy remains limited, 
however. For example, rectal dose volumes are a widely used 
planning tool, but published relationships between irradiated 
volumes and outcomes are inconsistent. 
The presentation is a strictly clinical overview of the factors 
that contribute to ano-rectal radiation injuries and outlines 
recent progress in their management. Symptomatology 
resulting from rarely cited injuries, such as to the per-rectal 
fat and the pelvic floor musculature, are also discussed. 
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Since the last 10 years 3D image-guided brachytherapy using 
CT, MRI, and/or ultrasound (US) has been introduced into 
clinical practice worldwide enabling conformation of the 
dose distribution to the target volume and avoidance of high 
dose to organs at risk (OAR). To be able to optimise the dose 
distribution in brachytherapy both the anatomy (target 
volume/OAR) and the applicator(s) should be correctly 
localised in the images. If the image modality does not 
enables both of these criteria the dose delivered the patient 
may be calculated incorrectly. Another important aspect is 
that the images should reflect the true situation at the time 
of the treatment. Due to the large dose gradient in 
brachytherapy, even small changes in the position of the 
applicator and/or anatomical structures may lead to 
discrepancies between planned and delivered dose. Usually, 
this is achieved with as short time as possible between 
imaging and treatment delivery. 
The optimal image modality to use is depending on the site 
to be treated as well as the geometry and the material of the 
applicator. For cervical cancer MR imaging is the optimal 
modality to discriminate soft tissue and tumour. Concepts for 
image guided cervical brachytherapy have been developed by 
GEC-ESTRO and T2 weighted MR imaging is the preferred 
modality. In an interobserver study the mean inter-
delineation distance of around 4 mm were found for the high 
risk CTV (HR CTV). The impact of these uncertainties for D90 
and D100 (dose to 90% and 100% of the volume) were 10% and 
19%, respectively.  
Post-implant dosimetry after permanent prostate seed 
implantation is usually based on CT imaging. However, MR 
imaging has superior soft tissue contrast and is some times 
used nowadays. In an interobserver study the dosimetric 
consequence of the delineation uncertainty was estimated to 
be 18% for the prostate D90 when T2 and T1 weighted MR 
images were used. This figure was increased to 23% when the 
delineation was done on CT images. 
Functional MR imaging, such as dynamic-enhanced MR, 
diffusion weighted imaging and MR spectroscopy, gives the 
opportunity to image microenvironmental characteristics of a 
tumour. Specific areas within the target volume with a high 
burden of disease or with biological characteristics indicating 
radioresistance may be targeted for higher dose delivery. 
Even though MR imaging is excellent for target delineation, 
localisation of the applicators (i.e. the source path) or the 
seeds could be challenging. Some applicators (e.g. steel 
applicators or shielded applicators) are not even MR 
compatible. In general it is easier to visualise the applicator 
and source(s) in CT images. For rigid MR compatible 
applicators (e.g. plastic tandem-ring-applicator) so called 
library applicator files could be used. Then applicator file, 
including information about the applicator surface 
dimensions and the source path, can be imported into the MR 
images and rotated and translated until it matches the 
images. In some situations the needle tip could be difficult to 
localise in MR images. Then supplementary imaging could be 
used (e.g. CT) and image registration should be performed 
with the aim of matching the applicator geometry and not 
the bony anatomy. The dosimetric consequences of 
uncertainties in the applicator localisation are smaller 
compared to consequences of uncertainties in the target 
delineation. For the HR CTV D90 an average of 2% change per 
mm displacement of a ring applicator has been found in all 
directions.  
Transrectal US (TRUS) is extensively used in prostate 
brachytherapy and gives an excellent view of the prostate 
gland. However, the presence of needles will preclude the 
image quality. Additionally, localisation of the needle tip 
could be challenging during needle reconstruction. 
TRUS-based brachytherapy procedure offer a method for 
interactive treatment planning and, thus, short time between 
imaging and treatment delivery. Several groups have 
developed methods for “in treatment room” imaging with 
both CT and MR. However, for the latter method, challenges 
due to non MR compatible equipment is substantial. 
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Purpose/Objective: The aim of this study is to analyze the 
effect of catheter displacement and anatomical variations 
(prostate and organs at risk) on the dose distribution in MRI 
guided single fraction high dose rate (HDR) focal 
brachytherapy of the prostate. 
Materials and Methods: Twenty-two patients were treated 
with MRI guided focal HDR brachytherapy (Iridium-192) in a 
single fraction of 19 Gy. A multiparametric MRI was used to 
define the tumor region and was matched with the 
intraoperative ultrasound (US). For the treatment, self-
anchoring umbrella catheters were used (1). For dose 
